首页> 外文期刊>Radiation Oncology Journal >Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration
【24h】

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration

机译:眼眶浸润性鼻窦癌患者需行新辅助化学放疗保存器官

获取原文
           

摘要

Purpose We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. Materials and Methods Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. Results Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. Conclusion For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.
机译:目的我们试图确定采用新辅助化学放疗(CRT)进行器官保存(OP)在已确定需要切除的鼻窦癌患者中是否可行。材料与方法从2005年至2014年,确定20例需要彻底根治的患者。14例行OP手术,6例接受了辅助CRT消灭。估计了无创生存(EFS),局部控制(LRC),无进展生存(PFS)和总体生存(OS)。结果5例(36%)接受OP的患者在手术时具有完全的疾病反应。接受OP的患者中位随访18.8个月,在2年时EFS为62%。在2年时,两组之间的LRC,PFS或OS均无显着差异(所有p> 0.050)。在接受OP的患者中观察到3级或更高的毒性(p = 0.003)。所有接受OP的患者均保留了视觉功能。结论对于鼻窦癌患者,OP可以避免肿瘤的灭绝,提供类似的疾病控制和改善的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号